Machina Capital S.A.S. Makes New $206,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)

Machina Capital S.A.S. acquired a new position in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 6,187 shares of the biotechnology company’s stock, valued at approximately $206,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. USA Financial Formulas purchased a new stake in Exelixis during the 4th quarter valued at $32,000. Principal Securities Inc. raised its stake in shares of Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the period. Kestra Investment Management LLC purchased a new position in shares of Exelixis during the 4th quarter worth about $39,000. Brooklyn Investment Group purchased a new position in shares of Exelixis during the 3rd quarter worth about $42,000. Finally, UMB Bank n.a. boosted its stake in shares of Exelixis by 68.4% during the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 553 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Stephens reaffirmed an “equal weight” rating and set a $29.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Wells Fargo & Company cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $36.00 price target for the company. in a research note on Monday, February 24th. Morgan Stanley raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $30.00 to $40.00 in a research note on Monday, January 27th. Stifel Nicolaus lifted their price target on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday, February 12th. Finally, Oppenheimer cut shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and an average price target of $37.24.

Insider Transactions at Exelixis

In other news, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the transaction, the chief financial officer now owns 779,607 shares of the company’s stock, valued at $28,174,996.98. The trade was a 3.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 140,343 shares of company stock valued at $5,177,234 in the last 90 days. Insiders own 2.85% of the company’s stock.

Exelixis Stock Performance

NASDAQ:EXEL opened at $38.58 on Monday. Exelixis, Inc. has a one year low of $20.14 and a one year high of $39.30. The firm has a market cap of $10.80 billion, a P/E ratio of 21.80, a P/E/G ratio of 1.13 and a beta of 0.57. The firm has a 50-day simple moving average of $34.99 and a 200-day simple moving average of $32.12.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.